Related Experiment Video

Updated: Jun 16, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

[Molecular targeted therapies in small-cell lung cancer]

A Levy1, G G Malouf, B Besse

  • 1Service des Innovations Thérapeutiques Précoces, Département de Médecine, Institut Gustave-Roussy, Université Paris-XI, Villejuif, France.

Bulletin Du Cancer
|January 23, 2010
PubMed

Insights

Small-cell lung cancer (SCLC) is aggressive but initially chemosensitive. Despite new targeted therapies, outcomes haven't surpassed standard chemotherapy, necessitating ongoing research for improved SCLC treatments.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Context:

  • Small-cell lung cancer (SCLC) exhibits high initial chemosensitivity but frequently relapses due to resistance.
  • The development of molecular targeted therapies has spurred numerous clinical trials in SCLC treatment.

Purpose:

  • To review pharmacological strategies aimed at improving survival for both localized and extensive SCLC.
  • To evaluate the efficacy of emerging targeted therapies against SCLC.

Summary:

  • Standard etoposide-cisplatin chemotherapy remains a benchmark for extensive SCLC.
  • Early trials of molecular targeted therapies have not shown improved outcomes compared to standard chemotherapy.
  • New therapeutic targets, including angiogenesis, signal transduction, cell cycle, and apoptosis pathways, are under investigation.

Impact:

  • Highlights the limitations of current targeted therapies in SCLC.
  • Identifies promising avenues for future SCLC drug development.
  • Emphasizes the need for novel treatment strategies to overcome therapeutic resistance in SCLC.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...